FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1955565662> ?p ?o ?g. }

• W1955565662 endingPage "37" @default.
• W1955565662 startingPage "327" @default.
• W1955565662 abstract "Radioimmunotherapy (RIT) can be performed with various radionuclides. We tested the stability, biodistribution, and therapeutic efficacy of various radioimmunoconjugates ((131)I, (88/90)Y, (177)Lu, and (186)Re) of chimeric antirenal cell cancer monoclonal antibody G250 (mAb cG250) in nude mice with subcutaneous renal cell cancer (RCC) tumors.The (88/90)Y and (177)Lu labeling procedures of cG250 conjugated with cyclic diethylenetriaminepentaacetic acid anhydride (cDTPA), isothiocyanatobenzyl-DTPA (SCN-Bz-DTPA), or 1,4,7,10-tetraazacyclododecanetetraacetic acid (DOTA) were characterized. Stability of the labeled conjugates in plasma at 37 degrees C was assessed. Biodistribution and therapeutic efficacy of labeled cG250 were compared in nude mice with SK-RC-52 human RCC xenografts.Both SCN-Bz-DTPA and DOTA were stable in vitro (<5% release of the radiolabel during 14 and 21 d of incubation) and in vivo (uptake in bone </= 1.5 percentage injected dose per gram [%ID/g] at 7 d after injection) when used to label (88)Y or (177)Lu to cG250. The DOTA conjugate was slightly but significantly more stable than SCN-Bz-DTPA at 7 d after injection. In vivo, these cG250 preparations showed high tumor uptake (70 +/- 15 %ID/g +/- SD at 7 d after injection). Maximum tumor uptake for (125)I-cG250 and (186)Re-mercaptoacetyltriglycine-(MAG3)-cG250 (<20 +/- 3 %ID/g +/- SD) was reached at 3 d after injection and was much lower in comparison with cG250 labeled with the residualizing radionuclides. Because the highest specific activities could be prepared using SCN-Bz-DTPA, and relatively low protein doses of cG250 could be administered without saturating the tumor, cG250-SCN-Bz-DTPA conjugates were used in RIT studies. In RIT experiments at maximum tolerated dose, tumor growth was delayed most effectively by cG250 labeled with (177)Lu, next most effectively by (90)Y and (186)Re (which were approximately equal), and least by (131)I (delayed by approximately 185, 125, 90, and 25 d, respectively). The best median survival (300 d) was observed for (177)Lu-SCN-Bz-DTPA-cG250. Median survival for control groups was <150 d.DOTA-conjugated radiolabeled antibodies were the most stable radioimmunoconjugates in vitro and in vivo as manifested by the lowest bone uptake. However, specific activity was higher for SCN-Bz-DTPA. The RIT studies clearly showed that the therapeutic efficacy of mAb cG250 labeled with (177)Lu, (90)Y, or (186)Re was superior to that of (131)I-cG250. The residualizing radionuclides (177)Lu and (90)Y led to higher radiation doses to the tumor and most likely are better candidates than conventionally radiolabeled (131)I for RIT with cG250 in patients with RCC." @default.
• W1955565662 created "2016-06-24" @default.
• W1955565662 creator A5012764804 @default.
• W1955565662 creator A5038420155 @default.
• W1955565662 creator A5045875431 @default.
• W1955565662 creator A5056620057 @default.
• W1955565662 creator A5070554692 @default.
• W1955565662 creator A5072881153 @default.
• W1955565662 creator A5089453603 @default.
• W1955565662 date "2004-02-01" @default.
• W1955565662 modified "2023-09-25" @default.
• W1955565662 title "Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re." @default.
• W1955565662 cites W1486452205 @default.
• W1955565662 cites W1771757368 @default.
• W1955565662 cites W1796352165 @default.
• W1955565662 cites W1841075178 @default.
• W1955565662 cites W1841139525 @default.
• W1955565662 cites W1905759932 @default.
• W1955565662 cites W1939179218 @default.
• W1955565662 cites W1945013834 @default.
• W1955565662 cites W1954572735 @default.
• W1955565662 cites W1973826816 @default.
• W1955565662 cites W1974370610 @default.
• W1955565662 cites W2011832860 @default.
• W1955565662 cites W2026411584 @default.
• W1955565662 cites W2029086462 @default.
• W1955565662 cites W2032808582 @default.
• W1955565662 cites W2058426435 @default.
• W1955565662 cites W2062222016 @default.
• W1955565662 cites W2073256585 @default.
• W1955565662 cites W2073610157 @default.
• W1955565662 cites W2079554499 @default.
• W1955565662 cites W2095637914 @default.
• W1955565662 cites W2119037600 @default.
• W1955565662 cites W2127098999 @default.
• W1955565662 cites W2132668316 @default.
• W1955565662 cites W2134354949 @default.
• W1955565662 cites W2136268570 @default.
• W1955565662 cites W2139641734 @default.
• W1955565662 cites W2150243921 @default.
• W1955565662 cites W2150384126 @default.
• W1955565662 cites W2152279343 @default.
• W1955565662 cites W2164905930 @default.
• W1955565662 cites W2168966763 @default.
• W1955565662 cites W2171749120 @default.
• W1955565662 cites W2256938482 @default.
• W1955565662 cites W2116049862 @default.
• W1955565662 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14960657" @default.
• W1955565662 hasPublicationYear "2004" @default.
• W1955565662 type Work @default.
• W1955565662 sameAs 1955565662 @default.
• W1955565662 citedByCount "38" @default.
• W1955565662 countsByYear W19555656622014 @default.
• W1955565662 countsByYear W19555656622015 @default.
• W1955565662 countsByYear W19555656622016 @default.
• W1955565662 countsByYear W19555656622017 @default.
• W1955565662 countsByYear W19555656622018 @default.
• W1955565662 countsByYear W19555656622020 @default.
• W1955565662 countsByYear W19555656622022 @default.
• W1955565662 crossrefType "journal-article" @default.
• W1955565662 hasAuthorship W1955565662A5012764804 @default.
• W1955565662 hasAuthorship W1955565662A5038420155 @default.
• W1955565662 hasAuthorship W1955565662A5045875431 @default.
• W1955565662 hasAuthorship W1955565662A5056620057 @default.
• W1955565662 hasAuthorship W1955565662A5070554692 @default.
• W1955565662 hasAuthorship W1955565662A5072881153 @default.
• W1955565662 hasAuthorship W1955565662A5089453603 @default.
• W1955565662 hasConcept C142724271 @default.
• W1955565662 hasConcept C150903083 @default.
• W1955565662 hasConcept C159654299 @default.
• W1955565662 hasConcept C185592680 @default.
• W1955565662 hasConcept C202751555 @default.
• W1955565662 hasConcept C203014093 @default.
• W1955565662 hasConcept C207001950 @default.
• W1955565662 hasConcept C2776146153 @default.
• W1955565662 hasConcept C2777472916 @default.
• W1955565662 hasConcept C2777807558 @default.
• W1955565662 hasConcept C2779931791 @default.
• W1955565662 hasConcept C2781278892 @default.
• W1955565662 hasConcept C2989005 @default.
• W1955565662 hasConcept C2993559085 @default.
• W1955565662 hasConcept C502942594 @default.
• W1955565662 hasConcept C542903549 @default.
• W1955565662 hasConcept C55493867 @default.
• W1955565662 hasConcept C71924100 @default.
• W1955565662 hasConcept C86803240 @default.
• W1955565662 hasConceptScore W1955565662C142724271 @default.
• W1955565662 hasConceptScore W1955565662C150903083 @default.
• W1955565662 hasConceptScore W1955565662C159654299 @default.
• W1955565662 hasConceptScore W1955565662C185592680 @default.
• W1955565662 hasConceptScore W1955565662C202751555 @default.
• W1955565662 hasConceptScore W1955565662C203014093 @default.
• W1955565662 hasConceptScore W1955565662C207001950 @default.
• W1955565662 hasConceptScore W1955565662C2776146153 @default.
• W1955565662 hasConceptScore W1955565662C2777472916 @default.
• W1955565662 hasConceptScore W1955565662C2777807558 @default.
• W1955565662 hasConceptScore W1955565662C2779931791 @default.
• W1955565662 hasConceptScore W1955565662C2781278892 @default.

• next